Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Abstract

BACKGROUND:

To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC).

METHODS:

A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed.

RESULTS:

Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group.

CONCLUSION:

This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

• Authors: Katherine C Fuh, Angeles A Secord, Kerri S Bevis, Warner Huh, Adam ElNaggar, Kevin Blansit, Rebecca Previs, Todd Tillmanns, Daniel S Kapp, John K Chan
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 139 Issue 3 Pg. 413-8 (Dec 2015) ISSN: 1095-6859 [Electronic] United States
• PMID: 26144600 (Publication Type: Comparative Study, Journal Article, Multicenter Study)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Taxoids
• liposomal doxorubicin
• Deoxycytidine
• Bevacizumab
• Polyethylene Glycols
• Topotecan
• Doxorubicin
• Cyclophosphamide
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bevacizumab (adverse effects, therapeutic use)
• Cyclophosphamide (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Disease-Free Survival
• Doxorubicin (administration & dosage, analogs & derivatives)
• Fallopian Tube Neoplasms (drug therapy, pathology)
• Female
• Humans
• Lymphatic Metastasis
• Middle Aged
• Neoplasm Recurrence, Local (diagnostic imaging, drug therapy)
• Neoplasms, Glandular and Epithelial (drug therapy)
• Ovarian Neoplasms (drug therapy, pathology)
• Peritoneal Neoplasms (drug therapy, pathology)
• Polyethylene Glycols (administration & dosage)
• Radiography
• Response Evaluation Criteria in Solid Tumors
• Retrospective Studies
• Survival Rate
• Taxoids (administration & dosage)
• Topotecan (administration & dosage)
• Young Adult
• Gemcitabine